CardiaTec, a biotech company based in Cambridge, UK, has raised $6.5 million in seed funding to accelerate the development of its computational drug discovery platform targeting cardiovascular disease. The round was led by Montage Ventures, with participation from Continuum Health Ventures, Laidlaw Ventures, APEX Ventures, and several high-profile individual investors, including Dr. Maximilien Levesque and Naheed Kurji.
With the latest round of funding, CardiaTec is well-positioned to make significant advancements in cardiovascular drug discovery, a field that has traditionally lagged in innovation.
CardiaTec is leveraging its proprietary platform to decode the complex biology of cardiovascular disease using large-scale human multi-omics data. Cardiovascular disease, responsible for 17.9 million deaths globally each year, remains a leading cause of death. The newly secured funding will enable CardiaTec to advance its drug discovery efforts and move novel therapeutic targets into preclinical development.
CEO and co-founder Raphael Peralta highlighted the potential of this approach: “By modeling the intricate biology of cardiovascular disease across multiple omic dimensions, we have the opportunity to develop new therapeutic strategies that challenge the current standard of care.”
CardiaTec’s platform integrates high-dimensional data across genomics, proteomics, epigenomics, and transcriptomics to provide a more comprehensive understanding of cardiovascular diseases. This computational approach is designed to overcome the limitations of traditional drug discovery methods.
The company has established a network of 65 hospitals across the U.S. and UK to collect human heart tissue, building the world’s largest multi-omics dataset for cardiovascular research. This resource is expected to fuel future innovations in cardiovascular therapeutics.
Todd Kimmel, Partner at Montage Ventures, described CardiaTec’s platform as “a game changer” in cardiovascular drug discovery, with the potential to identify novel drug targets for the world’s most deadly disease. He emphasized the company’s competitive edge, citing its proprietary data moat and strong connections within the pharmaceutical industry.
Founded in 2021 as a spin-out from the University of Cambridge’s Han Lab, CardiaTec’s leadership team includes CEO Raphael Peralta, CTO Prof. Namshik Han, and COO Thelma Zablocki. The team’s collective expertise spans leading organizations such as Bristol Myers Squibb, Cleveland Clinic, and Recursion Pharmaceuticals. The company’s founders were also recognized in the Forbes 30 Under 30 Europe list
